Moderna, Inc.: Moderna and Merck Announce mRNA-4157 in Combi

mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of distant metastasis or death by 65% (HR=0.347 [95% CI, 0.145-0.828]); one-sided p value=0.0063) compared to KEYTRUDA aloneThe DMFS results

Related Keywords

Canada , United States , Cambridge , Cambridgeshire , United Kingdom , American , Kyle Holen , Peter Dannenbaum , Colleen Hussey , Julie Cunningham , Stefan Klotter , Lavina Talukdar , Erich Rubin , Damini Chokshi , Youtube , Statement Of Merck Co Inc , Drug Administration , Brand Corporate Affairs , American Association For Cancer Research , American Society Of Clinical Oncology , Moderna Inc View , Merck Research Laboratories , Eastern Cooperative Oncology Group , Exchange Commission , Linkedin , Instagram , Facebook , Head Of Development , European Medicines Agency , Moderna Inc , Nasdaq , Merck Co Inc , Twitter , Clinical Oncology , Annual Meeting , Senior Vice President , Merck Research , Breakthrough Therapy Designation , Priority Medicines , American Association , Cancer Research , Performance Status , Selected Important Safety , Important Safety Information , Fatal Immune Mediated Adverse , Which Can Present With Diabetic , Nervous System , Connective Tissue , Patients With Multiple , Neck Squamous Cell , Bacillus Calmette Guerin , Mismatch Repair Deficient , Mismatch Repair Deficient Colorectal , Looking Statement , Securities Litigation Reform Act , Annual Report , Private Securities Litigation Reform Act , Prescribing Information , Medication Guide , Media Contacts , Investor Contacts , Vice President , Inc View , Stabile Ertr , Chart Profi Stefan Klotter , Blue Chips , Moderna , Merck , Nnounce , Rna , 157 , Combination , Ith , Keytruda , Remonstrated , Statistically , Significant , Linically , Meaningful , Improvement , Distant , Metastasis , Tree , Survival , Patients , Thigh , Risk ,